Key Drivers
- Cash Coverage
- Margin Pressure
- Leverage Watch
AIAI Summary
FMS looks less like a defensive healthcare staple and more like a fairly valued cash-generating turnaround, with upside tied to successful execution of its home-dialysis/digital-care shift and buybacks, while leverage, reimbursement pressure, and transformation costs remain the key reasons not to overpay today.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Coverage
- •Margin Pressure
- •Leverage Watch
FMS looks fairly attractive on price and cash flow, but modest profitability, leverage, and weaker Q1 2026 coverage make execution the key risk.
Price Behavior
Key Price Behavior Insights:
- •Uptrend intact
- •Strong support zone
- •Mid-23s resistance
Over the last month, FMS has trended higher and rebounded well, but it is now stalling under $23.70–$23.85 resistance, so the setup stays cautiously bullish unless that ceiling breaks.
Rebounded sharply from $22.61 on 2026-06-30 to $23.53 on 2026-07-02
Sentiment & News
Key News Insights:
- •Home dialysis push
- •Permitting progress
- •Technical milestones
FMS headlines point to Fresenius Medical Care accelerating its home-dialysis strategy with new digital and high-volume therapy offerings, while Focus Graphite advances key technical and permitting milestones at Lac Knife and Lac Tetepisca.
Overall, the news is modestly constructive as both companies show execution progress, with Fresenius expanding its care model and Focus Graphite de-risking development
Similar Companies in Healthcare
Other companies in the same sector with AI ratings